Compare KRO & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRO | CATX |
|---|---|---|
| Founded | 1916 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 602.9M | 569.6M |
| IPO Year | 2004 | 2018 |
| Metric | KRO | CATX |
|---|---|---|
| Price | $5.43 | $4.46 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $6.00 | ★ $12.00 |
| AVG Volume (30 Days) | 307.8K | ★ 1.5M |
| Earning Date | 03-09-2026 | 03-16-2026 |
| Dividend Yield | ★ 3.62% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,859,400,000.00 | N/A |
| Revenue This Year | $3.47 | $12.71 |
| Revenue Next Year | $11.59 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.08 | $1.60 |
| 52 Week High | $7.94 | $6.16 |
| Indicator | KRO | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 47.90 | 41.77 |
| Support Level | $5.14 | $3.24 |
| Resistance Level | $5.85 | $4.54 |
| Average True Range (ATR) | 0.32 | 0.36 |
| MACD | 0.00 | -0.15 |
| Stochastic Oscillator | 51.14 | 5.73 |
Kronos Worldwide Inc manufactures and sells titanium dioxide pigments. Titanium dioxide is a white inorganic pigment used in various products. The majority of Kronos' sales come from titanium dioxide used for coatings on automobiles, aircraft, machines, appliances, traffic paint, and in both commercial and residential interiors and exteriors. The second product category is titanium dioxide used for plastics such as packaging materials and food packaging, houseware, appliances, toys, and computer cases. The majority of revenue comes from the United States.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.